KraneShares MSCI All China Health Care Index ETF
KURE
New York Stock Exchange Arca- -
USD
- -
- -
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Sector
- Financial Services
- Industry
- Asset Management - Global
- Address
- 280 Park Avenue, 32nd Floor New York NY United States of America 10017
- IPO Date
- Feb 1, 2018
- CIK
- 0001547576
- Website
- kraneshares.com
- Similar Companies
- Business
- KraneShares MSCI All China Health Care Index ETF (KURE) is an exchange-traded fund that tracks the MSCI China All Shares Health Care 10/40 Index, providing investors with exposure to large-, mid-, and small-cap Chinese companies engaged in the healthcare sector across mainland China, Hong Kong, and the United States. The fund's core holdings include biotechnology firms such as Innovent Biologics Inc. and Akeso Inc.; general pharmaceuticals like Jiangsu Hengrui Pharmaceuticals and Hansoh Pharmaceutical Group; contract research organizations including WuXi Biologics Cayman Inc. and WuXi Apptec Co. Ltd.; medical device manufacturers such as Shenzhen Mindray Bio-Medical Electronics; and traditional Chinese medicine providers like Sino Biopharmaceutical; with top positions featuring Beone Medicines Ltd., Jiangsu Hengrui Pharmaceuticals, Innovent Biologics, WuXi Biologics, and Akeso as of late 2025. Launched on January 31, 2018, and listed on NYSE Arca, KURE maintains net assets of approximately $81 million, a net expense ratio of 0.65% (with waivers through August 1, 2026), and annual distributions. KraneShares, the fund's investment manager founded in 2013 and headquartered at 280 Park Avenue, 32nd Floor, New York, NY, with additional offices in San Francisco and London, specializes in China-focused ETFs blending U.S. expertise with local partnerships. Krane Funds Advisors, LLC, majority-owned by China International Capital Corporation (CICC) since a 2017 strategic alliance, issues KURE as part of a broader suite targeting China's growth themes, including internet, climate, and alternatives. In recent developments, KraneShares announced in late 2025 the planned closure of KURE due to its assets under management falling below prospectus minimums, alongside the KraneShares MSCI China ESG Leaders ETF (KESG), marking a significant portfolio rationalization; the fund had delivered year-to-date gains exceeding 34% through much of 2025 amid healthcare sector momentum from regulatory reprieves and biotech/biopharma advances. Concurrently, the firm expanded internationally by partnering with ICBC UBS International to list a KWEB-tracking ETF on the Hong Kong Stock Exchange (HKEX) in December 2025 across HKD, USD, and RMB counters, enhancing Asia-Pacific access to China internet strategies. KraneShares also published 2025 estimated per-share distributions for its ETF lineup and continued cross-listings, such as prior European expansions including a UCITS version of KURE on Borsa Italiana in 2022.